Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700157 | 0.83 | GRM5 (0.67) | GRM5NPC1TP53RAB9ADCTPP1 | |
| SCHEMBL4698325 | 0.83 | GRM5 (0.53) | GRM5NPC1MAPTPKMRAB9A | |
| SCHEMBL14200523 | 0.83 | GRM5 (0.53) | GRM5NPC1MAPTPKMRAB9A | |
| SCHEMBL13683938 | 0.81 | GRM5 (0.53) | GRM5NPC1MAPTRAB9A | |
| SCHEMBL4703496 | 0.80 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4701228 | 0.80 | GRM5 (0.72) | GRM5 | |
| SCHEMBL13683998 | 0.76 | GRM5 (1.00) | GRM5 | |
| SCHEMBL13683904 | 0.76 | GRM5 (0.57) | GRM5NPC1MAPTPKMRAB9A | |
| SCHEMBL5205386 | 0.76 | GRM5 (0.66) | GRM5NPC1MITFTP53MAPT | |
| SCHEMBL13683903 | 0.75 | GRM5 (0.46) | GRM5NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | claimed |
| EP-1434773-B1 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | claimed |
| US-7253190-B2 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK & CO., INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | claimed |
| EP-1434773-A4 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-01-12 | — | — | EP | claimed |
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2004-09-23 | — | — | US | claimed |
| EP-1434773-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003029210-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO. INC. (US) | 2003-04-10 | — | — | WO | claimed |
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| EP-1434773-B1 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7253190-B2 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK & CO., INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1434773-A4 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2004-09-23 | — | — | US | disclosed |
| EP-1434773-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003029210-A2 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO. INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | GRM5, GRM1, GRIK5 | GRM5 1/4885NPC1 3418/4885MITF 1731/4885 |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | GRM5 4705/4885NPC1 287/4885MITF 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.